Ernexa Therapeutics Inc. · NASDAQ:ERNA
Ernexa Therapeutics — Investor Presentation (July 2026)
24 slides from Ernexa Therapeutics's investor presentation, Jul 2, 2026
Slide 1: Breaking Through Defenses, Delivering Hope
ErneXa ( pat \ : Therapeutics™ Breaking Through Defenses, Delivering Hope Modulating the Immune System Through Synthetic Induced-Mesenchymal Stem Cell (iMSC) Therapies ernexatx.com Nasdaq: ERNA July 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement ErneXa Theropouties” This presentation (this “Presentation”) and any oral statements made in connection with this Presentation are for informational purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equi
Slide 3: Introduction & Company Overview
E- rneka Therapeutics* Breaking Through Defenses, Delivering Hope Introduction & Company Overview
Slide 4: Our Mission & Vision
Providing Hope Our Mission & Vision Transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatm
Slide 5: Ernexa Therapeutics: A Publicly Traded, Preclinical-Stage Company
Ernexa Therapeutics: A Publicly Traded, Preclinical-Stage Company Developing Synthetic iMSC Therapies with Tangible Milestones (IND Submission in Q3 2026) | ERNA-101 | IL-7_IL-15 Secreting iMSC For Oncology Indications (Lead Program) + Completed PoP studies and FDA pre-IND meeting with regulatory al
Slide 6: Pipeline Driving Next-Generation iMSC Therapies Across Solid Tumors & Autoimmune Disease
Pipeline Driving Next-Generation iMSC Therapies “e Across Solid Tumors & Autoimmune Disease ErneXa Advancing Towards First-in-Human (FIH) Study With Lead Program ERNA-101 by Q4 2026 Building a differentiated Uincoeppettis Indication Uae Preclinical Phase 1 Phase 2 eee iMSC-based portfolio to Area Ca
Slide 7: Our Genetically-Engineered Synthetic Induced MSCs (iMSC) Therapy
Our Genetically-Engineered “Synthetic” Induced MSCs (iMSC) Therapy Enable Multiple Infusions From a Single Donor, Significantly Decreasing Erne%a Cost of Goods Per Dose erie RNA-mediated ing | Transfected with synthetic RNA molecules =i il =i ee eeaaes leaves encoding reprogramming factors (Oct4, So
Slide 8: ERNA-101: New Category of Immunotherapy that Overcomes Limitations of MSCs & Cytokines
ERNA-101: New Category of Immunotherapy that Overcomes The Limitations of Both Naturally Occurring MSCs & Cytokines EEE) | 100% cure Rate REXEL > 20-fold C. DUAL MECHANISM OF T/NK CELLS ACTIVATION: Mechanism 2: Myeloid TME Reprogramming Mechanism 1: in ovarian tumor xenograft model Supraphysiologic
Slide 9: ERNA-101: Pro-Inflammatory Fusion Cytokines Secreting iMSC
E- rneka Therapeutics* Breaking Through Defenses, Delivering Hope ERNA-101: Pro-Inflammatory Fusion Cytokines (IL-7_IL-15) Secreting iMSC for Allogeneic Therapy
Slide 10: ERNA-101: Pro-Inflammatory Fusion Cytokines (IL-7_IL-15) Secreting iMSC for Allogeneic Therapy
ERNA-101: Pro-Inflammatory Fusion Cytokines (IL-7_IL-15) : Secreting iMSC for Allogeneic Therapy EmeXa In combination with anti PD-1 ab demonstrated 100% survival and complete tumor clearance in ovarian cancer models; advancing towards phase 1 trial in Q4-2026 Mechanism of Action ERNA-101 leverages
Slide 11: A Significant Opportunity in Platinum-Resistant Ovarian Cancer (PROC)
A Significant Opportunity in Platinum-Resistant Ovarian Cancer (PROC)* PROC is a subset of recurrent ovarian cancer, defined by disease progression within six months after completing platinum-based chemotherapy Ovarian Cancer: Incidence: 21,010 (2026)! Prevalence: 254,621 (2023)! Incidence of PROC:
Slide 12: Mechanism of Action of ERNA-101: Leveraging Intrinsic Tumor-Homing Ability of MSCs
Mechanism of Action of ERNA-101: Leveraging the Intrinsic Tumor- ot ErneXa Homing Ability of MSCs to Create a Trojan Horse for Cancer Terence ERNA-101 consists of IMSCs engineered to secrete a novel immune-enhancing fusion of the cytokines IL-7 and IL-15 (IL-7_IL-15) The IL-7_IL-15 fusion cytokine (
Slide 13: Breakthrough Preclinical Result: ERNA-101 + Anti PD-1 ab Exhibited 100% Survival
Breakthrough Preclinical Result: ERNA-101 + Anti PD-1 ab Exhibited 100% Survival & Complete Tumor Clearance in Ovarian Cancer Model ErneXa Combination of ERNA-101 with Anti-PD1 Antibody Leads to Complete Regressions and Long-Term Survival in ID8YC-OVA Syngeneic Mouse Model of Ovarian Cancer es Contr
Slide 14: Planned First-In-Human Phase Open Label, Single Arm Study
Planned First-In-Human Phase 1 Open Label, Single Arm Study of ERNA-101 + Pembrolizumab and Bevacizumab ERNA-101 (IP) Monotherapy Dose-Escalation - Q3W | 1 2 3 4 5 6 Uv 8 9 10 11 12 Scan Scan Biopsy Biopsy po cycle tT cycle 2 cycles | cycles | cycle 5— Cycle 17 1 2 2 4 5) 6 7 8 9 10 #11 12 13 14 one
Slide 15: ERNA-201: Anti-Inflammatory Cytokine (IL-10) Secreting iMSC for Allogeneic Therapy
E- rneka Therapeutics* Breaking Through Defenses, Delivering Hope ERNA-201: Anti-Inflammatory Cytokine (IL-10) Secreting iMSC for Allogeneic Therapy
Slide 16: ERNA-201: Anti-Inflammatory Cytokine (IL-10) Secreting iMSC For Allogeneic Therapy
ERNA-201: Anti-Inflammatory Cytokine (IL-10) “e Secreting iMSC For Allogeneic Therapy ErneXa Designed to deliver IL-10 directly to inflamed tissues, rebalancing immune activity and driving durable remission in autoimmune disease g 9 4 G Future Milestones Mechanism of Action Target Indications Curren
Slide 17: Persistent Unmet Need in Rheumatoid Arthritis (RA) Despite Therapeutic Advances
Persistent Unmet Need in Rheumatoid Arthritis (RA) Despite Therapeutic Advances ErneXa Chronic, systemic autoimmune disease characterized by persistent joint inflammation, progressive tissue destruction, and loss of Limitations of Current Therapies: function Incomplete Disease Control: RA: 30-40% of
Slide 18: ERNA-201 Selectively Home to the Site of Inflammation and Deliver Anti-Inflammatory IL-10
ERNA-201 Selectively Home to the Site of Inflammation and ot. Deliver Anti-Inflammatory IL-10: Putative Mechanism of Action Ernexa ERNA-201 (IL-10 Expressing iMSC) els Impressive efficacy as systemic “nical MO recombinant IL-10 therapy . fa prectin + ERNA-201 consists of iMSCs engineered to secrete
Slide 19: Study of ERNA-201 in Rheumatoid Arthritis (RA) Mouse Model
Study of ERNA-201 in Rheumatoid Arthritis (RA) Mouse Model Purpose: To determine if ERNA-201 (IL-10-CCR2 iMSCs) treatment can decrease the severity of the arthritic phenotype in a CIA mouse model Timeline: Paw Score: Grouping and Dose 1 pases ; ‘CR2 0.5E6 (3 dose) vs 1.0E6 (1 dose) ial saa a i = -e
Slide 20: Trading Snapshot, Development Plan, Investment Summary & Concluding Remarks
E- rneka Therapeutics” Breaking Through Defenses, Delivering Hope Trading Snapshot, Development Plan Investment Summary & Concluding Remarks
Slide 21: Trading Snapshot
Nasdaq: ERNA: Trading Snapshot ErneXa. Sufficient Capital to Fund Clinical Development Through Multiple Value Driving Milestones, Including the Launch of the First-in- Human Study Key Highlights Market Cap Avg. Volume Shares ~$9.2 MM ~$8 MM ~1.7 MM 1.17 MM As of June 30, 2026 - Share Price of $6.92
Slide 22: Ernexa's Development Plan for Next Months
Ernexa’s Development Plan for Next 12 Months: Several Near 7 Term Tangible Milestones with Two Clinical Programs in 2027 ErneXa PoP Studies (Completed) xx Pre-IND Meeting (completed) (geannsannn=== =, Interim Data {Start of Phase T Study Readout ERNA-101* CMC Studies* for IND Submission/ ical Grade
Slide 23: Investment Summary
Investment Summary Rapidly Transitioning to a Clinical-Stage Company With Multiple Programs Entering First-in- Human Studies in the Near Term The Platform Lead Programs & Near-Term Milestones Upcoming Plans ERNA-101 + Lead program entering FIH studies in Q4- 2026 for PROC + Innovative off-the-shelf,
Slide 24: We Are Driving Towards Meaningful Outcomes
We Are Driving Towards Meaningful Outcomes; oe More Time for the Moments That Matter ErneXa * Despite decades of progress, outcomes for platinum- H C) P resistant ovarian cancer remain devastating + Families carry the emotional burden We aim to change what it means to live with . J 4 ovarian cancer,
Ernexa Therapeutics — Investor Presentation (July 2026) on 6ix